Control Bionics

Control Bionics Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Control Bionics (CBL.AX) as of Nov 20, 2026 is 69.89 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 83.06 % — a change of -15.86% (lower).

Cash Conversion

69.89 %

YoY

-15.86%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Control Bionics is 2025 69.89 % . Cash Conversion Rate (OCF/Net Income) of Control Bionics was 2024 83.06 % . It decreases by -15.86% lower compared to the previous year.

The Control Bionics Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
99.83 AUD
Jan 1, 2019
100.71 AUD
Jan 1, 2020
85.94 AUD
Jan 1, 2021
112.39 AUD
Jan 1, 2022
112.88 AUD
Jan 1, 2023
80.40 AUD
Jan 1, 2024
83.06 AUD
Jan 1, 2025
69.89 AUD
The Control Bionics Cash Conversion history
YEARCash ConversionYoY
69.89 %-15.86%
83.06 %+3.31%
80.40 %-28.77%
112.88 %+0.44%
112.39 %+30.78%
85.94 %-14.67%
100.71 %+0.89%
99.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Control Bionics Stock analysis

What does Control Bionics do? Control Bionics Ltd. generates revenue through the sale of its NeuroNode Trilogy, NeuroNode Duo, Eye-gaze Duo, and DROVE systems, which are designed for patients with communication impairments due to conditions like motor neuron disease and amyotrophic lateral sclerosis. The company's NeuroNode technology detects brain signals to skeletal muscles, converting them into EMG output that enables wireless communication via personal computers for speech, email, and texting. Its products integrate with eye-gaze technology, allowing cursor movement on screens as a mouse alternative, with the NeuroNode functioning as the mouse button. These systems are primarily purchased by healthcare providers and rehabilitation centers serving patients with severe motor disabilities. The company's core products include NeuroNode Trilogy, NeuroNode Duo, Eye-gaze Duo, and DROVE, each tailored to specific communication and mobility needs. NeuroNode Trilogy and NeuroNode Duo focus on EMG-based communication, while Eye-gaze Duo combines eye-tracking with the NeuroNode for cursor control. DROVE is another core system that supports additional functionalities. Healthcare institutions and rehabilitation facilities are the primary buyers, as they deploy these technologies to assist patients with conditions such as motor neuron disease and amyotrophic lateral sclerosis who require augmentative and alternative communication solutions. Control Bionics Ltd. targets medical and rehabilitation sectors, specifically those dealing with patients suffering from motor neuron disease, amyotrophic lateral sclerosis, and similar conditions. The NeuroNode technology is sold as a complete system, including wireless wearable devices and integration with eye-gaze systems, to enable seamless communication through computer-controlled functions. Revenue is derived from direct sales of these systems to healthcare providers who serve individuals with compromised verbal and text-based communication abilities. Control Bionics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Control Bionics stock

Cash Conversion Rate (OCF/Net Income) of Control Bionics is 69.89 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Control Bionics changed from 83.06 % to 69.89 %, representing a -15.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Control Bionics since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Control Bionics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Control Bionics

All Key Metrics — Control Bionics